Distinct immune landscapes characterize highly versus minimally invasive brain metastases
Authors:
- Sarah M. MaritanSMSarah M. Maritan
- Elham KarimiEKElham Karimi
- Matthew DanknerMDMatthew Dankner
- Aldo Hernandez-CorchadoAHAldo Hernandez-Corchado
- Miranda W. YuMYMiranda W. Yu
- Matthew G. AnnisMAMatthew G. Annis
- Morteza RezanejadMRMorteza Rezanejad
- Bridget LiuBLBridget Liu
- Nebras KoudiehNKNebras Koudieh
- Emilie PichetteEPEmilie Pichette
- Parvaneh FallahPFParvaneh Fallah
Open Access
- 26 March 2026
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (10)
Abstract
Brain metastases (BrMs) occur in approximately 30% of cancer patients, causing nearly one-fifth of cancer deaths. While immune checkpoint inhibitors (ICIs) benefit some BrM patients, responses remain highly variable. This variability partly reflects distinct histopathological growth patterns that include minimally invasive (MI) and highly invasive (HI) brain BrMs. Here we show that MI BrMs exhibit robust immune infiltration, whereas HI lesions are immunosuppressed. However, histological differentiation between MI and HI can be challenging because of subjective margin assessment. Here, using highly multiplexed spatial proteomics on 119 tumor sections from 46 patients with BrMs, we identify CHI3L1 as a key mediator of the immunosuppressive microenvironment in HI BrMs. In preclinical models, genetic deletion of CHI3L1 converts immune-cold metastases into lymphocyte-rich, ICI-responsive lesions infiltrated by granzyme B + CD8 + T cells. In BrM patients treated with ICI, immunohistochemical quantification of CHI3L1 expression was a stronger predictor of ICI response than traditional MI/HI classification. Thus, CHI3L1 represents a promising biomarker and therapeutic target for BrMs.Keywords
Funding Information
- Canadian Institutes of Health Research (CIHR PJT-175066)
- Canadian Institutes of Health Research (CIHR PJT-175066)
This publication has 73 references indexed in Scilit:
- Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to ImmunotherapyJAMA Network Open, 2023
- Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune CellsCell, 2020
- Comprehensive network map of interferon gamma signalingJournal of Cell Communication and Signaling, 2018
- Interaction of astrocytes and T cells in physiological and pathological conditionsBrain Research, 2015
- Astrocytes facilitate melanoma brain metastasis via secretion of IL‐23The Journal of Pathology, 2015
- Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT‐like phenotype change and MMP‐9‐mediated degradation of E‐cadherinJournal of Cellular Biochemistry, 2011
- Elevated pretreatment serum concentration of YKL‐40—An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancerCancer, 2010
- Elevated serum level of YKL‐40 is an independent prognostic factor for poor survival in patients with metastatic melanomaCancer, 2006
- Prognostic value of PINP, bone alkaline phosphatase, CTX‐I, and YKL‐40 in patients with metastatic prostate carcinomaThe Prostate, 2005
- Astrocytes protect the CNS: antigen-specific T helper cell responses are inhibited by astrocyte-induced upregulation of CTLA-4 (CD152)Journal of Molecular Medicine, 2004